Titel

Merkliste
1 Ergebnisse

Dabrafenib plus trametinib versus dabrafenib monotherapy in..:

Long, GV ; Flaherty, KT ; Stroyakovskiy, D...
Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 28 (7), pp. 1631 - 1639. , 2017

Link: https://repository.icr.ac.uk/handle/internal/663

RT Journal
T1 <Title>Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study</Title>

UL https://suche.suub.uni-bremen.de/peid=base-ftinstcancerres:oai:repository.icr.ac.uk:internal_663&Exemplar=1&LAN=DE
				
A1 Long, GV
A1 Flaherty, KT
A1 Stroyakovskiy, D
A1 Gogas, H
A1 Levchenko, E
A1 de Braud, F
A1 Larkin, J
A1 Garbe, C
A1 Jouary, T
A1 Hauschild, A
A1 Chiarion-Sileni, V
A1 Lebbe, C
A1 Mandalà, M
A1 Millward, M
A1 Arance, A
A1 Bondarenko, I
A1 Haanen, JBAG
A1 Hansson, J
A1 Utikal, J
A1 Ferraresi, V
A1 Mohr, P
A1 Probachai, V
A1 Schadendorf, D
A1 Nathan, P
A1 Robert, C
A1 Ribas, A
A1 Davies, MA
A1 Lane, SR
A1 Legos, JJ
A1 Mookerjee, B
A1 Grob, J-J
YR 2017
K1 Humans
K1 Melanoma
K1 Skin Neoplasms
K1 Disease Progression
K1 Oximes
K1 Imidazoles
K1 Pyridones
K1 Pyrimidinones
K1 Proto-Oncogene Proteins B-raf
K1 Antineoplastic Combined Chemotherapy Protocols
K1 Protein Kinase Inhibitors
K1 Disease-Free Survival
K1 Treatment Outcome
K1 Drug Administration Schedule
K1 Risk Factors
K1 Double-Blind Method
K1 Mutation
K1 Time Factors
K1 Kaplan-Meier Estimate
K1 Biomarkers
K1 Tumor
JF Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 28 (7), pp. 1631 - 1639
LK http://dx.doi.org/https://repository.icr.ac.uk/handle/internal/663
DO https://repository.icr.ac.uk/handle/internal/663
SF ELIB - SuUB Bremen

Export

RefWorks (nur Desktop-Version!)
Flow (Zuerst in Flow einloggen, dann importieren)